<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9424">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05698134</url>
  </required_header>
  <id_info>
    <org_study_id>2020/3087</org_study_id>
    <nct_id>NCT05698134</nct_id>
  </id_info>
  <brief_title>Rotational Thromboelastometry (ROTEM™) Guided Transfusion for Elective Procedures in Patients With Cirrhosis (REduCe): An Open Label Randomized Controlled Trial.</brief_title>
  <acronym>REduCe</acronym>
  <official_title>Rotational Thromboelastometry (ROTEM™) Guided Transfusion for Elective Procedures in Patients With Cirrhosis (REduCe): An Open Label Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changi General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      REDuCe is designed to evaluate the role of ROTEM™ in determining the need and the amount of&#xD;
      pre-emptive blood products use in patients with cirrhosis undergoing elective procedures&#xD;
      compared to the current standard of care. The secondary aim of this study is to evaluate&#xD;
      ROTEM™ parameters in patients with acute decompensation, acute on chronic liver failure and&#xD;
      acute liver failure and to co-relate it with the conventional coagulation tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with cirrhosis who meets eligibility criteria will be divided into two groups&#xD;
&#xD;
        1. Those who are undergoing elective procedures will be randomized into 1:1 ratio into&#xD;
           either standard of care (institutional transfusion protocol) or ROTEM guided protocol.&#xD;
           Baseline ROTEM will be obtained before and after blood product transfusion.&#xD;
&#xD;
        2. Those who are not for elective procedures and does not meet criteria for randomization&#xD;
           will be entered into data collection for secondary endpoints analysis. These patients&#xD;
           will have baseline ROTEM before transfusion and post transfusion ROTEM in those who&#xD;
           require blood prodducts transfusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">May 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized into two parallel groups:&#xD;
First group will receive standard of care based on institutional protocol for blood product transfusion Second group will receive ROTEM guided protocol for blood product transfusion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in amount of blood products transfused</measure>
    <time_frame>24 months</time_frame>
    <description>The difference in amount/volume of blood products used(fresh frozen plasma in mls, cryoprecipitate in units and platelets in units) used in patients with cirrhosis undergoing elective procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural bleeding complications</measure>
    <time_frame>24 months</time_frame>
    <description>1. Peri-procedural bleeding complications (e.g. immediate, and delayed bleeding) defined as overt bleeding or haemoglobin drop requiring transfusion with a target of 8 g/dL.&#xD;
Immediate Bleeding (&lt;24 hours of procedure)&#xD;
Delayed bleeding (&gt; 24 hours of procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion related adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse events are defined as any side effect occurring within 6 hours of blood product infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of stay</measure>
    <time_frame>24 months</time_frame>
    <description>Total hospital length of stay (in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day and 90-day survival</measure>
    <time_frame>24 months</time_frame>
    <description>Survival rate at 30-day and 90-day from time of procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic Complications</measure>
    <time_frame>24 months</time_frame>
    <description>Thrombotic events such as portal vein thrombosis, stroke which may be secondary to blood product transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related complications-other than bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Non-bleeding related complications, specific to procedure such as pneumothorax will be reviewed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive blood products transfusion based on prevailing institution protocol, which is based on Platelet count and coagulation parameters (APTT, PT/INR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROTEM guided Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive blood products transfusion based on ROTEM results</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ROTEM</intervention_name>
    <description>ROTEM is a commercially available whole blood Viscoelastic-Haemostatic Assay(VHA) point-of-care, global and dynamic haemostasis assessment tests that measures the viscoelastic changes occurring during the haemostatic process. They provide real-time, comprehensive reflection of the interaction between plasma, blood cells and platelets. It display hypo or hyper-coagulable features in patients with cirrhosis. It is widely used prior to cardiac, obstetric, trauma and liver transplant surgery to assess and correct for coagulation defects.</description>
    <arm_group_label>ROTEM guided Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with Cirrhosis undergoing elective procedure must meet all following criterias.&#xD;
&#xD;
          1. Patients undergoing the following elective procedures will be included in the study&#xD;
&#xD;
               1. Gastroscopy with endoscopic variceal ligation&#xD;
&#xD;
               2. Colonoscopy with polypectomy and endoscopic mucosal resection&#xD;
&#xD;
               3. ERCP with sphincterotomy&#xD;
&#xD;
               4. Percutaneous liver biopsy&#xD;
&#xD;
               5. Biopsy of other sites (excluding liver)&#xD;
&#xD;
               6. Hepatic venous pressure gradient with or without liver biopsy&#xD;
&#xD;
               7. Elective Transjugular Intrahepatic Portosystemic Shunt&#xD;
&#xD;
               8. Portal Vein embolization&#xD;
&#xD;
               9. Trans-arterial chemo-embolization (TACE)&#xD;
&#xD;
              10. Thermal ablation of hepatocellular carcinoma&#xD;
&#xD;
              11. Large volume paracentesis&#xD;
&#xD;
              12. Central venous catheter insertion&#xD;
&#xD;
              13. Thoracentesis&#xD;
&#xD;
          2. Age: Older than 21 years&#xD;
&#xD;
          3. Coagulopathy based on conventional coagulation tests which is defined as&#xD;
&#xD;
               1. INR &gt; 1.5 and/or aPTT &gt; 1.5x ULN for PTT and/or&#xD;
&#xD;
               2. Platelets &lt; 50,000/mm3/uL&#xD;
&#xD;
          4. Patients with acute decompensation, acute on chronic liver failure and acute liver&#xD;
             failure.&#xD;
&#xD;
          5. Able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Emergency procedures. (defined as life-saving procedures)&#xD;
&#xD;
          2. On-going bleeding&#xD;
&#xD;
          3. Under 21 years of age&#xD;
&#xD;
          4. Inability to obtain informed consent from patients&#xD;
&#xD;
          5. Coagulation disorders (other than those relating to liver disease)&#xD;
&#xD;
          6. Patients on anticoagulant medications (e.g. warfarin, enoxaparin, rivaroxaban,&#xD;
             dabigatran, apixaban, heparin, clexane etc.)&#xD;
&#xD;
          7. Patients on anti-platelet aggregation agents other than aspirin (e.g. clopidogrel,&#xD;
             ticagrelor)&#xD;
&#xD;
          8. Active malignancy except hepatocellular carcinoma&#xD;
&#xD;
          9. Patients who have received FFP, platelet transfusion, cryoprecipitate within last 7&#xD;
             days&#xD;
&#xD;
         10. Patients with stage 4 or 5 chronic kidney disease&#xD;
&#xD;
         11. Patients receiving renal replacement therapy&#xD;
&#xD;
         12. Patients with active sepsis as defined by ACPP-SCCM criteria (21).&#xD;
&#xD;
         13. Pregnant Women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahul Kumar, MBBS</last_name>
      <phone>65 6788 8833</phone>
      <email>rahul.kumar@singhealth.com.sg</email>
    </contact>
    <contact_backup>
      <phone>65 6788 8833</phone>
      <email>rahul.kumar@singhealth.com.sg</email>
    </contact_backup>
    <investigator>
      <last_name>Rahul Kumar, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chin Kimg Tan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 15, 2023</study_first_submitted>
  <study_first_submitted_qc>January 24, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 24, 2023</last_update_submitted>
  <last_update_submitted_qc>January 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ROTEM</keyword>
  <keyword>Invasive Procedure</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Blood Product</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

